Belite Bio (BLTE) Form 144 Filed for 30,000 ADS Sale on NASDAQ
Rhea-AI Filing Summary
Form 144 filing for Belite Bio, Inc. (BLTE) reports a proposed sale of 30,000 American Depositary Shares (each representing one ordinary share) through J.P. Morgan Securities LLC on NASDAQ with an aggregate market value of $1,902,600 and an approximate sale date of 08/21/2025. The filer acquired the 30,000 ADS on 03/07/2025 by exercising stock options and paid cash on that date. The filer states there were no securities sold in the past three months attributable to the same person, and the notice includes the standard Rule 144 representation about lack of undisclosed material information.
Positive
- None.
Negative
- None.
Insights
TL;DR: Insider plans to sell 30,000 ADS valued at $1.9M after exercising options; transaction is routine but noteworthy for share supply.
The filing documents a proposed sale of 30,000 ADS acquired by stock option exercise on 03/07/2025 and scheduled for sale on 08/21/2025 through J.P. Morgan Securities LLC. This records an increase in potential public float of the issuer by 30,000 ADS. The filing does not disclose the identity of the selling person, the filers holdings after the sale, or any trading plan adoption date. As provided, there are no reported sales in the prior three months for the account named.
TL;DR: Form 144 appears to follow Rule 144 disclosure for an option exercise and proposed sale; no compliance exceptions noted in the form itself.
The notice supplies the required elements for a Rule 144 filing: class of security, broker name and address, number of shares, aggregate market value, acquisition date and nature (stock option exercise), payment method (cash), and proposed sale date and exchange. The filer affirms they are not aware of undisclosed material adverse information. The form does not include a stated Rule 10b5-1 plan adoption date or signature block details in the provided content.